移植：利妥昔单抗诱导预防 HLA 抗体反弹。
Transplantation: rituximab induction for prevention of HLA-antibody rebound.
机构信息
Department of Medicine and Department of Transplant Surgery, University of Pittsburgh Medical Center, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.
出版信息
Nat Rev Nephrol. 2014 Dec;10(12):682-3. doi: 10.1038/nrneph.2014.179. Epub 2014 Oct 7.
PMID:25287429
Abstract
Desensitization therapy enables HLA-incompatible transplantation. However, desensitized patients have an increased risk of antibody-mediated rejection, and the presence of donor-specific antibodies (DSAs) is associated with poor outcomes. A new study has assessed the effect of rituximab induction on DSA production in kidney transplant recipients with high immunological risk.
摘要
脱敏治疗可实现 HLA 不相容的移植。然而，脱敏患者发生抗体介导排斥反应的风险增加，且供体特异性抗体（DSA）的存在与不良结局相关。一项新研究评估了利妥昔单抗诱导治疗对高免疫风险的肾移植受者 DSA 产生的影响。
Zotero 插件